

JP Morgan Healthcare Conference

January 15, 2025

Rěclūdo (Latin) transitive verb III conjugation 1 to open 2 to open up, to disclose, to reveal, to unlock

Unlocking New Therapeutic Possibilities

Unlocking Previously Undruggable SH2 Domains of High Value Targets in Inflammatory Diseases

Differentiated candidates in validated pathways & blockbuster markets



- Sanofi partnership
- Validated by IL-4Rα and IL-13 biologics



- Wholly-owned
- Validated by JAK & TYK2 inhibitors




- Wholly-owned
- Validated by BTK kinase inhibitors

OPERATIONAL STRENGTH	Experienced drug developers Well-capitalized to value-driving milestones
	Sanofi option: 50-50 US profit share

PROPRIETARY PLATFORM DRIVES OPTIONALITY

120 human SH2 domains; coveted targets previously considered "undruggable" Fuels robust pipeline and multiple partnering opportunities

Experienced Leadership Team



\$102M Series A





Nick Lydon

Strategic Collaboration with Sanofi for STAT6 Inhibitor



Certain U.S. co-promotion activities

U.S. co-promotion and ROW commercialization

Significant Unmet Medical Needs in Inflammatory Disease Remain

>60 M patients diagnosed globally each year with immune-related inflammatory disease; potential for rapid market expansion

Significant unmet needs persist to close efficacy gaps and elevate standard of care

Risk of **infection** and **other serious events** with current therapies pose major **safety barriers** that limit addressable population

Self-injection can be **burdensome** and **reduces compliance for many** patients


A diverse range of sub-populations have **no suitable therapeutic option** and remain untreated

SH2 Domains Have Previously Been Deemed "Undruggable"

Significant opportunity in targeting SH2 domain proteins

Src Homology 2 (SH2) domains are highly conserved protein domains that have long been recognized as attractive drug targets

- Small protein modules made up of ~100 amino acids
- 120 human SH2 domains
- Play a key role in mediating protein-protein interactions
- The SH2 domain of STAT proteins is required for:
 - Binding to cytokine receptors
 - Dimerization of STAT proteins



Recludix Platform: Integrated Proprietary Technologies & New Chemical Approaches

 Custom SH2 Domain Targeting DNA-Encoded Libraries

 Discovery and SAR DELs
 Hundreds of molecules

Prodrug Modality Expertise

Drives enhanced target coverage

High Quality Lead Compounds

Proprietary DEL Selection & SAR Analysis

Rapid massively parallel determination of structure-activity relationships

Structure-Based Design

Proprietary co-crystallography systems






SH2 Domain Screening Tool

Unique panel of Drives SH2 domain assays selectivity


STAT SH2 Domain Inhibition Enables a Best-in-Class Product Profile







STAT6

STAT6 is a First- and Best-In-Class Opportunity to Selectively Target Th2 Inflammatory Disease Pathways



Opportunity to Serve Large Patient Populations in High-Value Markets with a Uniquely Differentiated Product





LARGE POPULATIONS

Targeting broad, established patient populations with persistent unmet needs

DIFFERENTIATED PRODUCT

Patient-friendly oral formulation may enable treatment beyond those currently served by injectable agents

Source: GlobalData 2023, ClearView HealthCare Partners

COPD: Chronic obstructive pulmonary disease, PN: Prurigo nodularis, CRSwNP: Chronic rhinosinusitis with nasal polyps

R

STAT6 Inhibitor REX-8756 is Highly Potent and Selective in Biochemical and Cellular Assays



Recludix Pharma 1	2
---------------------	---

	Biochemical potency (SH2scan K _D)	Cellular potency (pSTAT6 IC ₅₀ in human PBMCs)	Biochemical STAT family selectivity	Cellular selectivity (PBMCs)	SH2 domain selectivity
REX-8756	0.04 nM	0.72 nM (IL-4) 0.19 nM (IL-13)	>1,000X vs. STAT1/2/3/4/5	>1,000X vs. STAT1/2/3/4/5	

STAT6 Inhibitor Demonstrates Biologic-Like Selectivity and Differentiates from JAK Inhibitors

Direct selective STAT6 inhibition provides greater selectivity than currently approved JAK inhibitors


		General adaptive immune response	Defense against viruses and bacteria	Defense against extracellular pathogens	Defense against parasites and mediation of antibody responses	Erythropoiesis	Thrombopoiesis
		T Cell Activation (CD25)	Th1 Cell Function (IFNγ)	Th17 Cell Function (IL-17A)	Th2 Cell Function (IL-5)	EPO-Induced STAT5-Driven Transcription	TPO-Induced STAT5-Driven Transcription
STAT6 Inhibitor	REX-8756	>3,000 nM	>1,000 nM	>2,500 nM	19 nM	>10,000 nM	>10,000 nM
IL-4 / IL-13 Antagonist	Dupilumab	>10,000 nM	>1,000 nM	>1,000 nM	26 nM	>1,000 nM	>1,000 nM
	Abrocitinib	1,300 nM	900 nM	73 nM	80nM	3,200 nM	2,800 nM
JAK Inhibitors	Upadacitinib	39 nM	36 nM	7.4 nM	4.3 nM	69 nM	20 nM
	Baricitinib	110 nM	210 nM	25 nM	15 nM	56 nM	42 nM

T CELL FUNCTION

Recludix Pharma JPM Morgan Healthcare Conference 2023 Recludix Pharma data on file, March 2023 **HEMATOLOGIC HOMEOSTASIS**

STAT6 Inhibitor Fully Inhibits IL-4/13 Stimulated STAT6-Driven Biomarkers in Human PMBCs

IL-4 induced CD23 activation




IL-4 induced TARC

REX-8756 Achieves Complete pSTAT6 Inhibition with Once Daily Dosing and is Well Tolerated in Dog 7-Day Study

Efficacious dose at >80% pSTAT6 PD modulation

Oral, QD dosing

Oral, BID dosing




- Highly selective pSTAT6 inhibition, no off-target pSTAT1 or pSTAT3 impact observed
- Well tolerated at all dose levels

Recludix STAT6 Inhibitors Achieve Deep and Durable pSTAT6 Inhibition In Vivo without STAT6 Protein Degradation in Mice

- Recludix compounds achieve dose-dependent, rapid, and durable pSTAT6 inhibition in blood and tissues
- Reversible pSTAT6 inhibition achieves exquisite targeting of type-2 inflammation without STAT6 protein degradation

In vivo pSTAT6 inhibition without protein degradation




Single dose PK/PD study

- Samples collected 4hr post single dose
- Whole blood and splenocytes ex vivo stimulated with IL-4 to induce STAT6 pathway activation
- Total STAT6 and pSTAT6 quantified by flow cytometry

STAT6 Tool Compound REX-4671 Has Comparable Efficacy to Combined Anti-IL-4/13 Biologics in Dermatitis Model

- REX-4671 dose dependently inhibits pSTAT6 and significantly reduced skin inflammation in chemicalinduced dermatitis model
- Comparable in vivo efficacy to the combination of anti-IL-4/13 surrogate antibodies




*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001


Spleen pSTAT6 inhibition

Skin inflammation

Prophylactic REX-4671 Demonstrates Comparable Efficacy to Combined Anti-IL-4/13 Biologics in OVA-Asthma Model

REX-4671 demonstrates comparable efficacy to combined anti-IL-4/13 rodent surrogate antibodies






anti-IL-4_ anti-IL-13



BTK

Selective Targeting Has the Potential to Yield Superior Efficacy and Safety in Chronic Inflammatory Diseases



>13M TOTAL PATIENT IMPACT

DIFFERENTIATED RELATIVE TO TRADITIONAL TKI APPROACH

Targeting SH2 domain leads to best-in-class selectivity to enable improved safety margins


SH2 approach disrupts the central scaffolding function of BTK to deeply inhibit pro inflammatory signaling and widen the therapeutic window

Prodrug mechanism enhances target coverage to drive improved efficacy

CSU: Chronic spontaneous urticaria, RA: Rheumatoid arthritis, SLE: Systemic lupus erythematosus, MS: Multiple sclerosis


BTK SH2 Inhibitor is First-In-Class with Differentiated Profile Relative to Traditional TKIs







BTK SH2 Inhibitors Abrogate Mast Cell Activation in In Vivo Model of Chronic Urticaria


BTK SH2 inhibitors demonstrate strong dose-dependent efficacy



Vascular leakiness (Evan's dye extravasation)







** p < 0.1, *** p < 0.001, **** p < 0.0001



Highlights and Upcoming Milestones

Highlights and Near Term Milestones



- Successfully drugged previously "undruggable" SH2 domains
- Advanced STAT6 inhibitor in global partnership with Sanofi
 - Potent, selective, reversable, and orally bioavailable compounds
 - Favorable differentiation from IL-4/IL-13 biologics and JAK/TYK2 inhibitors
 - In vivo efficacy and target modulation, without protein degradation, in inflammation disease models
- Advancing STAT3 and BTK SH2 domain inhibitor programs towards the clinic



STAT6

- GLP toxicology studies 1H25
- IND submission 2H25
- Phase 1 study initiation 2H25



Thank you

www.recludixpharma.com info@recludix.com bd@recludix.com



Unlocking New Therapeutic Possibilities